JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Harvard Bioscience Inc

Gesloten

SectorGezondheidszorg

0.5 2.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.49

Max

0.52

Belangrijke statistieken

By Trading Economics

Inkomsten

1.1M

-1.2M

Verkoop

141K

21M

Winstmarge

-5.978

Werknemers

330

EBITDA

1M

1.2M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+300% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-3.2M

22M

Vorige openingsprijs

-1.54

Vorige sluitingsprijs

0.5

Nieuwssentiment

By Acuity

100%

0%

337 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Harvard Bioscience Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 feb 2026, 23:11 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Marktinformatie

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Acquisities, Fusies, Overnames

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Winsten

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Acquisities, Fusies, Overnames

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Acquisities, Fusies, Overnames

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Acquisities, Fusies, Overnames

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Marktinformatie

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Winsten

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Winsten

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Winsten

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Winsten

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Winsten

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Winsten

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Marktinformatie

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Vergelijking

Prijswijziging

Harvard Bioscience Inc Prognose

Koersdoel

By TipRanks

300% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 USD  300%

Hoogste 2 USD

Laagste 2 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harvard Bioscience Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.3 / 0.3401Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

337 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat